THE EFFECTIVENESS OF MULTI-COMPONENT ANTI-TUBERCULOSIS DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS

<p><em><span>In order to study the effectiveness of multicomponent fixed-dose anti-tuberculosis drugs in the treatment of pulmonary tuberculosis, we examined 22 patients with infiltrative pulmonary tuberculosis, while the control group consisted of 25 patients with infiltrative pulmonary tuberculosis. A multicomponent anti-tuberculosis drug consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol was prescribed to patients in phase 1. Patients in the control group received rifampicin + isoniazid + ethambutol + pyrazinamide separately for 2-3 months. At the outpatient stage, the main group received a multicomponent drug containing R450H300 for a period of 4 months, whereas the control group took these drugs separately. </span></em></p> <p><em><span>Dynamic observations showed that in the main group, the indicators of the decrease in clinical symptoms of intoxication and respiratory manifestations, decrease in MBT release, and positive radiological dynamics did not differ from the control group of patients who received the drugs separately. </span></em></p>